摘要
鼻咽癌(NPC)是一类具有地域性、民族性和种族分布的癌症。某些遗传、种族和环境因素与鼻咽癌的发病机制有关和,更重要的是,在大多数病人中发现有EB病毒(EBV)的存在。由于没有特异性的症状,NPC病人只有在晚期才能得到诊断,因此,其治疗效果不佳。目前,由于化疗和放疗的低生存率、严重的并发症、肿瘤转移和复发等原因,治疗该癌症需要制定更好的治疗方案。最近的研究表明,表观遗传机制如DNA甲基化、组蛋白修饰和小分子RNA在EBV基因组以及在宿主细胞会发生改变,这可能发生在鼻咽癌的发生和发展之前。组蛋白乙酰转移酶(HATs)和组蛋白去乙酰化酶(HDAC)介导的组蛋白乙酰化和去乙酰化能调节基因表达和某些细胞学过程。HDACs还参与维持EBV的潜伏周期,因此,HDAC抑制剂(HDACi)是EBV激活的有效诱导剂,这对裂解蛋白的表达十分关键,当在单独使用或添加其他抗肿瘤药物治疗EBV相关的恶性肿瘤,这可以提供新的治疗靶点以及介导增强癌细胞的杀死率。最近,FDA批准的三种HDACi已用于临床治疗T细胞淋巴瘤,而其他一些药物则在临床试验中,这使组蛋白修饰成为靶向治疗的较好选择。本文总结了NPC表观遗传机制改变,并侧重介绍了用于靶向治疗的组蛋白修饰。
关键词: 表观遗传学,DNA甲基化,组蛋白去乙酰化酶抑制剂、组蛋白修饰、microRNA分子治疗,鼻咽癌。
Current Medicinal Chemistry
Title:Histone Modifications as Molecular Targets in Nasopharyngeal Cancer
Volume: 23 Issue: 2
Author(s): Sukanya Shyamasundar, S. Thameem Dheen and B. Huat Bay
Affiliation:
关键词: 表观遗传学,DNA甲基化,组蛋白去乙酰化酶抑制剂、组蛋白修饰、microRNA分子治疗,鼻咽癌。
摘要: Nasopharyngeal carcinoma (NPC) is a cancer of the nasopharyngeal epithelium with distinct geographical, ethnic and racial distribution. Several genetic, ethnic and environmental risk factors, have been implicated in nasopharyngeal pathogenesis and of significance, is the Epstein - Barr virus (EBV)- latent infection observed in most patients. Patients with NPC are typically diagnosed only in advanced stages due to non-specific symptoms, and hence, they respond poorly to therapy. Currently, low survival rates, severe complications, tumour metastasis and recurrence following chemo-radiotherapy, delineate the need for better therapeutic options to combat the disease. Recent studies have shown that epigenetic mechanisms such as DNA methylation, histone modifications and microRNAs, which are altered in the EBV genome as well as in the host cells, may underlie the initiation and progression of NPC. Histone acetylation and deacetylation which are mediated by enzymes, namely histone acetyl transferases (HATs) and histone deacetylases (HDACs), are known to regulate gene expression and several cellular processes. HDACs are also involved in maintaining the EBV latent cycle and thus, HDAC inhibitors (HDACi) are potent inducers of EBV reactivation, which is critical for the expression of the lytic proteins, thereby providing novel targets for therapy, as well as mediating enhanced killing of cancer cells, when used alone or along with additional anti-cancer agents in EBV associated malignancies. Recently, three FDA- approved HDACi have been used for the treatment of T-cell lymphoma, while several others are in clinical trials, making histone modifications excellent candidates for targeted therapy. In this review, we summarize the epigenetic mechanisms altered in NPC, with a focus on histone modifications for targeted therapy.
Export Options
About this article
Cite this article as:
Sukanya Shyamasundar, S. Thameem Dheen and B. Huat Bay , Histone Modifications as Molecular Targets in Nasopharyngeal Cancer, Current Medicinal Chemistry 2016; 23 (2) . https://dx.doi.org/10.2174/0929867323666151106125631
DOI https://dx.doi.org/10.2174/0929867323666151106125631 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Immunosuppressant Drugs and Covid-19: Associated Risks, Drug-Drug Interactions and Contraindications
Coronaviruses Mining the Adenovirus "Virome" for Systemic Oncolytics
Current Pharmaceutical Biotechnology Selected Natural and Synthetic Phenolic Compounds with Antileishmanial Activity: A Five-year Review
Current Bioactive Compounds Current Progresses in Metal-based Anticancer Complexes as Mammalian TrxR Inhibitors
Anti-Cancer Agents in Medicinal Chemistry Antibodies for Therapeutic Uses and the Evolution of Biotechniques
Current Medicinal Chemistry Alternatives to Conventional Vaccines - Mediators of Innate Immunity
Current Drug Targets Strategies for the Biological Evaluation of Gold Anticancer Agents
Anti-Cancer Agents in Medicinal Chemistry Selection and Characterization of Human Anti-MAGE-A1 scFv and Immunotoxin
Anti-Cancer Agents in Medicinal Chemistry Diagnostic Imaging of Fetal and Neonatal Abdominal and Soft Tissue Tumors
Current Pediatric Reviews Folate-Linked Lipid-Based Nanoparticle for Targeted Gene Delivery
Current Drug Delivery Targeting Vesicle Trafficking: An Important Approach to Cancer Chemotherapy
Recent Patents on Anti-Cancer Drug Discovery The Medical Potential of Antimicrobial Peptides from Insects
Current Topics in Medicinal Chemistry Covid-19 in Man: A Very Dangerous Affair
Endocrine, Metabolic & Immune Disorders - Drug Targets Angiogenesis Inhibitors and Radiation in Multimodality Cancer Therapy: Preclinical and Clinical Studies
Current Angiogenesis (Discontinued) Is the Clinical Use of Cannabis by Oncology Patients Advisable?
Current Medicinal Chemistry Biomarker Diversity, Validation and Clinical Translation: Tenets for Emergent Personalized Medicine Initiatives
Current Pharmacogenomics and Personalized Medicine Towards Multifunctional Synthetic Vectors
Current Gene Therapy Targeted Inhibition of Rictor/mTORC2 in Cancer Treatment: A New Era after Rapamycin
Current Cancer Drug Targets Stress Related Neuroendocrine Influences in Ovarian Cancer
Current Cancer Therapy Reviews Disruptive Nanozyme Technology for Futuristic Bio-Medical and Bio-imaging Applications
Current Nanoscience